Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Revenue (2016 - 2025)

Historic Revenue for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $339.0 million.

  • Haemonetics' Revenue fell 274.72% to $339.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year decrease of 402.18%. This contributed to the annual value of $1.4 billion for FY2025, which is 395.47% up from last year.
  • As of Q4 2025, Haemonetics' Revenue stood at $339.0 million, which was down 274.72% from $327.3 million recorded in Q3 2025.
  • Haemonetics' Revenue's 5-year high stood at $348.5 million during Q4 2024, with a 5-year trough of $225.0 million in Q2 2021.
  • Over the past 5 years, Haemonetics' median Revenue value was $314.8 million (recorded in 2023), while the average stood at $302.2 million.
  • As far as peak fluctuations go, Haemonetics' Revenue crashed by 564.51% in 2021, and later skyrocketed by 2400.53% in 2022.
  • Quarter analysis of 5 years shows Haemonetics' Revenue stood at $239.9 million in 2021, then grew by 27.26% to $305.3 million in 2022, then increased by 10.14% to $336.2 million in 2023, then rose by 3.66% to $348.5 million in 2024, then fell by 2.75% to $339.0 million in 2025.
  • Its Revenue was $339.0 million in Q4 2025, compared to $327.3 million in Q3 2025 and $321.4 million in Q2 2025.